HK1197251A1 - Methods of treatment with arginine deiminase - Google Patents

Methods of treatment with arginine deiminase

Info

Publication number
HK1197251A1
HK1197251A1 HK14110829.0A HK14110829A HK1197251A1 HK 1197251 A1 HK1197251 A1 HK 1197251A1 HK 14110829 A HK14110829 A HK 14110829A HK 1197251 A1 HK1197251 A1 HK 1197251A1
Authority
HK
Hong Kong
Prior art keywords
treatment
methods
arginine deiminase
deiminase
arginine
Prior art date
Application number
HK14110829.0A
Other languages
English (en)
Chinese (zh)
Inventor
John Bomalaski
Bor-Wen Wu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1197251A1 publication Critical patent/HK1197251A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
HK14110829.0A 2012-04-04 2014-10-29 Methods of treatment with arginine deiminase HK1197251A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261620368P 2012-04-04 2012-04-04
PCT/US2012/039979 WO2013151568A1 (fr) 2012-04-04 2012-05-30 Méthodes de traitement par une arginine déiminase

Publications (1)

Publication Number Publication Date
HK1197251A1 true HK1197251A1 (en) 2015-01-09

Family

ID=49300886

Family Applications (2)

Application Number Title Priority Date Filing Date
HK14110829.0A HK1197251A1 (en) 2012-04-04 2014-10-29 Methods of treatment with arginine deiminase
HK15105765.5A HK1205150A1 (en) 2012-04-04 2015-06-17 Methods of treatment with arginine deiminase

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15105765.5A HK1205150A1 (en) 2012-04-04 2015-06-17 Methods of treatment with arginine deiminase

Country Status (13)

Country Link
US (3) US9731028B2 (fr)
EP (2) EP3782653A1 (fr)
JP (4) JP2014521602A (fr)
KR (1) KR101638226B1 (fr)
CN (1) CN103797025B (fr)
AU (1) AU2012330497B2 (fr)
BR (1) BR112013028365B1 (fr)
CA (1) CA2834083C (fr)
ES (1) ES2828656T3 (fr)
HK (2) HK1197251A1 (fr)
SG (1) SG194641A1 (fr)
TW (3) TW201735943A (fr)
WO (1) WO2013151568A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022801A1 (fr) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Administration de petites molécules à l'aide d'un dispositif thérapeutique implantable
EP2640360A2 (fr) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Formulations d'agents thérapeutiques pour des dispositifs implantés
TW201735943A (zh) 2012-04-04 2017-10-16 普拉瑞斯集團 利用精胺酸去亞胺酶之治療方法
EP2968113B8 (fr) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systèmes pour l'administration intra-oculaire entretenue de composés à faible solubilité provenant d'un implant de système de pose d'orifice
WO2014151982A2 (fr) 2013-03-15 2014-09-25 Polaris Group Arginine désiminase à réactivité croisée réduite envers les anticorps anti-adi-peg 20 pour le traitement du cancer
EP3052116B1 (fr) * 2013-10-04 2021-05-05 Ann, David K. Arginase i, arginase ii, ou adi en combinaison avec la doxorubicine pour l'utilisation dans le traitement du cancer du sein
WO2015143006A1 (fr) 2014-03-18 2015-09-24 Tdw Group Adi pégylée chimères manipulée et procédés d'utilisation
CN114106186A (zh) 2014-07-08 2022-03-01 瑞华药业集团 精氨基琥珀酸合成酶的抗体和相关方法
US9474756B2 (en) * 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114522225A (zh) 2014-09-16 2022-05-24 瑞华药业集团 用于癌症治疗的对adi-peg20抗体具有降低的交叉反应性的精氨酸脱亚氨酶
KR20180127632A (ko) * 2015-12-03 2018-11-29 란자테크 뉴질랜드 리미티드 가스 발효 아세토젠에서의 효율을 개선하기 위한 아르기닌 보충
TW201825122A (zh) * 2016-07-05 2018-07-16 開曼群島商北極星藥業集團股份有限公司 用精胺酸耗盡劑進行之組合癌症免疫療法
TW202308683A (zh) * 2016-11-02 2023-03-01 開曼群島商北極星藥業集團股份有限公司 聚乙二醇化精胺酸脫亞胺酶之調配物
CN108324951B (zh) * 2018-04-16 2021-05-25 薛剑峰 一种精氨酸脱亚胺酶注射剂及其制备方法
CN110694076B (zh) * 2019-09-09 2021-02-09 浙江大学 一种羟基氯喹两亲性聚合物药物前体、制备方法及其应用
EP4069280A4 (fr) * 2019-12-02 2024-01-03 Univ Hong Kong Polytechnic Procédés pour induire un jeûne intermittent et moduler l'autophagie
WO2022000151A1 (fr) * 2020-06-29 2022-01-06 Vision Global Holdings Limited Méthode de traitement de sous-types de lma à l'aide d'agents de déplétion de l'arginine

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6635462B1 (en) 1997-05-12 2003-10-21 Phoenix Pharmacologies, Inc. Mutated form of arginine deiminase
US6183738B1 (en) 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
IT1298918B1 (it) 1998-02-20 2000-02-07 Mendes Srl Uso di batteri dotati di arginina deiminasi per indurre apoptosi e/o ridurre una reazione infiammatoria e composizioni farmaceutiche
WO2002009741A1 (fr) 2000-07-27 2002-02-07 Angiolab, Inc. Composition pharmaceutique comprenant une arginine deiminase destinee a inhiber l'angiogenese
EP1337630A2 (fr) * 2000-11-28 2003-08-27 Phoenix Pharmacologics, Inc. Arginine deiminase modifiee
AU2003282883B2 (en) 2002-11-18 2008-12-04 Polaris Group Methods for inhibiting viral replication in vivo
AU2004235382A1 (en) * 2003-04-29 2004-11-11 Wyeth Methods for diagnosing AML and MDS differential gene expression
PT1778723E (pt) 2004-08-17 2013-01-25 Regeneron Pharma Formulações de antagonista de il-1
CN101002945B (zh) 2006-01-20 2012-09-05 清华大学 一种用于肿瘤治疗的新型复合物
US8546329B2 (en) * 2006-03-22 2013-10-01 Chugai Seiyaku Kabushiki Kaisha Erythropoietin solution preparation
EP2068923A4 (fr) * 2007-03-30 2010-11-24 Medimmune Llc Anticorps presentant des profils de desamidation reduits
US20100197944A1 (en) 2007-07-04 2010-08-05 Dr. Reddy's Laboratories Limited Docetaxel process and polymorphs
US20090238813A1 (en) 2007-12-28 2009-09-24 Board Of Regents, The University Of Texas System Compositions And Methods For Engineered Human Arginine Deiminases
WO2010083312A2 (fr) * 2009-01-14 2010-07-22 The Trustees Of The University Of Pennsylvania Biomarqueur de micro-arn dans le cancer
WO2011053871A2 (fr) 2009-10-30 2011-05-05 Life Technologies Corporation Essai multi-amorces pour détection de mycoplasme
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
AU2011260016B2 (en) 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
US8663967B2 (en) 2011-08-22 2014-03-04 Jiangsu T-Mab Biopharma Co., Ltd. Arginine deiminase mutant and preparation and application thereof
TW201735943A (zh) 2012-04-04 2017-10-16 普拉瑞斯集團 利用精胺酸去亞胺酶之治療方法
WO2014151982A2 (fr) 2013-03-15 2014-09-25 Polaris Group Arginine désiminase à réactivité croisée réduite envers les anticorps anti-adi-peg 20 pour le traitement du cancer

Also Published As

Publication number Publication date
AU2012330497A1 (en) 2013-10-24
HK1205150A1 (en) 2015-12-11
EP3782653A1 (fr) 2021-02-24
US9333268B2 (en) 2016-05-10
TW201611843A (en) 2016-04-01
US10525142B2 (en) 2020-01-07
TWI577386B (zh) 2017-04-11
EP2834262B1 (fr) 2020-09-02
US20150132278A1 (en) 2015-05-14
TW201735943A (zh) 2017-10-16
WO2013151568A1 (fr) 2013-10-10
US9731028B2 (en) 2017-08-15
ES2828656T3 (es) 2021-05-27
CN103797025B (zh) 2018-03-23
JP2015172083A (ja) 2015-10-01
CN103797025A (zh) 2014-05-14
US20180154008A1 (en) 2018-06-07
TW201340979A (zh) 2013-10-16
AU2012330497B2 (en) 2016-08-04
US20150231272A1 (en) 2015-08-20
CA2834083A1 (fr) 2013-10-10
KR20150035350A (ko) 2015-04-06
BR112013028365A2 (pt) 2016-11-29
SG194641A1 (en) 2013-12-30
EP2834262A1 (fr) 2015-02-11
CA2834083C (fr) 2018-05-22
JP6534205B2 (ja) 2019-06-26
KR101638226B1 (ko) 2016-07-08
BR112013028365B1 (pt) 2022-04-05
JP2017008115A (ja) 2017-01-12
JP2018104470A (ja) 2018-07-05
JP2014521602A (ja) 2014-08-28
EP2834262A4 (fr) 2015-11-11

Similar Documents

Publication Publication Date Title
HRP20181628T1 (hr) Spojevi i postupci za njihovu upotrebu
HK1205150A1 (en) Methods of treatment with arginine deiminase
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
HK1204272A1 (en) Methods of treating pediatric metabolic syndrome
EP2912178A4 (fr) Super-activateurs et procédés d'utilisation de ceux-ci
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
HK1205759A1 (en) Treatment of biomass
EP2717855A4 (fr) Procédés de traitement
EP2852397A4 (fr) Variants d'huwentoxine iv et procédés d'utilisation
EP2888227A4 (fr) Nouveaux promédicaments et leurs méthodes d'utilisation
HK1214958A1 (zh) 凝血酶溶液及其使用方法
HK1202053A1 (en) Treatment of liver conditions
GB201309274D0 (en) Treatment Of Fuel
GB201102248D0 (en) Treatment of bipolar disorder
EP2822594A4 (fr) Procédés de traitement par des anticorps anti-angiopoïétine-2
HK1205695A1 (en) Paramyxovirus and methods of use
GB201207907D0 (en) Treatment of depression
IL277033A (en) Thrombin solution and methods of using it
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment